Axogen (AXGN) vs NovoCure (NVCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Axogen (AXGN) has outperformed NovoCure (NVCR) over the past year, gaining 110.8% versus a loss of 0.9%. Over five years, AXGN leads with a +165.6% price change compared with -87.3% for NVCR. Axogen is the larger company by market cap ($2.12 billion vs $1.66 billion), about 1.3 times the size.
Axogen converts more of its revenue into profit, with a net margin of -7.0% versus -20.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AXGN | NVCR |
|---|---|---|
| Share price | $36.18 | $14.22 |
| Market cap | $2.12B | $1.66B |
| 1-day change | +0.39% | -3.00% |
| YTD return | +10.54% | +9.98% |
| 1-year return | +110.84% | -0.91% |
| 5-year return | +165.64% | -87.33% |
| Forward P/E | 52.59 | — |
| EPS (TTM) | $-0.67 | $-1.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $225.21M | $655.35M |
| Revenue growth (YoY) | +20.21% | +8.28% |
| Net income (latest FY) | $-15.70M | $-136.23M |
| Gross margin | 74.31% | 74.54% |
| Operating margin | -3.49% | -23.47% |
| Net margin | -6.97% | -20.79% |
| 52-week high | $52.91 | $21.45 |
| 52-week low | $15.27 | $9.82 |
| Distance from 52-week high | -31.62% | -33.71% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +48.76% | +88.89% |
| Average volume | 1.22M | 1.42M |
| Shares outstanding | 58.67M | 116.45M |
| Employees | 622 | 1,605 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AXGN has outperformed NVCR by 111.7 percentage points over the past year.
- Axogen is more profitable, keeping -7.0 cents of every revenue dollar as net income versus -20.8 cents for NovoCure.
- Axogen grew revenue faster in its latest fiscal year (+20.21% vs +8.28%).
About Axogen
AXGN stock →Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 622 employees
About NovoCure
NVCR stock →NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax.
Health Care · Medical/Dental Instruments · 1,605 employees
AXGN vs NVCR FAQ
Which is bigger, Axogen or NovoCure?
Axogen (AXGN) is larger, with a market capitalization of $2.12B compared with $1.66B for NovoCure (NVCR).
Which stock has performed better over the past year, AXGN or NVCR?
AXGN returned +110.84% over the past 12 months, compared with -0.91% for NVCR (price return, excluding dividends). Past performance does not predict future results.
Are Axogen and NovoCure in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Electromedical & Electrotherapeutic Apparatus for Axogen and Medical/Dental Instruments for NovoCure.